Literature DB >> 27734102

Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera.

S Farmer1, V V Shanbhogue2, S Hansen2, C I Stahlberg3, H Vestergaard4, A P Hermann2, H Frederiksen4,5.   

Abstract

In this cross-sectional study of 45 patients with myeloproliferative neoplasms, we found no evidence of secondary osteoporosis.
INTRODUCTION: Patients with essential thrombocythemia (ET) and polycythaemia vera (PV) are at increased risk of fractures but the underlying mechanisms have not been settled. We conducted a study to assess bone mineral density, microarchitecture, estimated bone strength and global bone turnover in 45 patients with ET or PV.
METHODS: Patients were evaluated in a cross-sectional study with dual energy X-ray absorptiometry (DXA) at the hip and spine; high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal radius and distal tibia; and biochemical markers of bone turnover including pro-collagen type 1 N-terminal pro-peptide, osteocalcin, C-terminal cross-linking telopeptide of type 1 collagen and bone-specific alkaline phosphatase. Also, 45 healthy comparisons, matched on age, height and weight with each patient were included as control subjects.
RESULTS: Patients and comparisons had almost identical BMDs: 0.96 (IQR: 0.85-1.07) g/cm2 and 0.96 g/cm2 (IQR: 0.86-1.05 g/cm2), respectively. As well all microarchitecture and estimated bone strength measures were highly similar in the two groups. Levels of bone turnover markers were within reference values in patients.
CONCLUSION: These results reveal no evidence of secondary osteoporosis among patients with ET or PV. The mechanism behind the increased fracture risk in ET or PV patients remains unknown.

Entities:  

Keywords:  Bone mineral density; Chronic myeloproliferative neoplasms; Essential thrombocythemia; Microarchitecture; Polycythemia vera

Mesh:

Year:  2016        PMID: 27734102     DOI: 10.1007/s00198-016-3788-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  42 in total

1.  Visual grading of motion induced image degradation in high resolution peripheral computed tomography: impact of image quality on measures of bone density and micro-architecture.

Authors:  J B Pialat; A J Burghardt; M Sode; T M Link; S Majumdar
Journal:  Bone       Date:  2011-10-13       Impact factor: 4.398

2.  Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?

Authors:  Hans Carl Hasselbalch
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

Review 3.  Bone densitometry.

Authors:  Kwang J Chun
Journal:  Semin Nucl Med       Date:  2011-05       Impact factor: 4.446

4.  The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

Authors:  Ruben A Mesa; Joyce Niblack; Martha Wadleigh; Srdan Verstovsek; John Camoriano; Sunni Barnes; Angelina D Tan; Pamela J Atherton; Jeff A Sloan; Ayalew Tefferi
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

5.  Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.

Authors:  Hans C Hasselbalch
Journal:  Expert Rev Hematol       Date:  2014-02-13       Impact factor: 2.929

6.  Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

Authors:  S R Cummings; D M Black; M C Nevitt; W Browner; J Cauley; K Ensrud; H K Genant; L Palermo; J Scott; T M Vogt
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

7.  Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT.

Authors:  Stinus Hansen; Ellen M Hauge; Jens-Erik Beck Jensen; Kim Brixen
Journal:  J Bone Miner Res       Date:  2013-04       Impact factor: 6.741

8.  Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

Authors:  Ayalew Tefferi; Paola Guglielmelli; Dirk R Larson; Christy Finke; Emnet A Wassie; Lisa Pieri; Naseema Gangat; Rajmonda Fjerza; Alem A Belachew; Terra L Lasho; Rhett P Ketterling; Curtis A Hanson; Alessandro Rambaldi; Guido Finazzi; Juergen Thiele; Tiziano Barbui; Animesh Pardanani; Alessandro M Vannucchi
Journal:  Blood       Date:  2014-07-18       Impact factor: 22.113

Review 9.  Bone involvement and osteoporosis in mastocytosis.

Authors:  Maurizio Rossini; Roberta Zanotti; Ombretta Viapiana; Gaia Tripi; Giovanni Orsolini; Luca Idolazzi; Patrizia Bonadonna; Donatella Schena; Luis Escribano; Silvano Adami; Davide Gatti
Journal:  Immunol Allergy Clin North Am       Date:  2014-03-13       Impact factor: 3.479

10.  Bone mineral density thresholds for pharmacological intervention to prevent fractures.

Authors:  Ethel S Siris; Ya-Ting Chen; Thomas A Abbott; Elizabeth Barrett-Connor; Paul D Miller; Lois E Wehren; Marc L Berger
Journal:  Arch Intern Med       Date:  2004-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.